Introduction
A regional hospital in California experienced a noticeable increase in hospital-acquired pressure injuries (HAPIs), leading to severe patient discomfort and higher costs. Each year, approximately 2.5 million HAPIs occur in U.S. hospitals, significantly impacting patient outcomes. Studies show that HAPIs are associated with a 57% longer length of stay and a 22% higher rate of 30-day readmissions in acute-care settings*. In response, the hospital’s care team decided to explore respiratory solutions that prioritized both therapeutic efficacy and patient comfort. This led them to Sleepnet’s Veraseal®3 Full Face Mask, a non-invasive ventilation (NIV) mask featuring AIR°gel® technology—designed to improve patient compliance while lowering the risk of pressure-related facial injuries.
* All data and findings presented in this use case are derived from PubMed Central’s article, Effectively Addressing Hospital-Acquired Pressure Injuries With a Multidisciplinary Approach (October 1, 2024; accessed March 19, 2025), which provides insights into pressure injuries across all body areas, not just facial injuries related to NIV or CPAP mask usage.
Background
HAPIs remain a persistent issue in American healthcare, significantly impacting both patient outcomes and hospital costs.
- Financial Burden: The cost of treating HAPIs in a 100-bed hospital can exceed $1.8 million annually. Severe cases cost between $75,000 and $150,000 per patient (PubMed 2024, Effectively Addressing HAPIs with a Multidisciplinary Approach).
- Nursing Challenges: Addressing HAPIs requires considerable staff time and expertise, which can be difficult given nursing shortages and the increasing complexity of patient care (PubMed 2024, Effectively Addressing HAPIs with a Multidisciplinary Approach).
- Impact on Patient Care: These injuries increase patient discomfort and recovery time, contributing to longer hospital stays and higher readmission rates.
The Challenge
Traditional NIV masks often contribute to skin irritation and pressure ulcers, particularly when used for extended periods. The hospital identified several key challenges:
- Risk of Pressure Ulcers: Prolonged mask use can create pressure points, leading to facial ulcers that require additional medical attention and prolonged healing times.
- Patient Discomfort: Many NIV masks can cause discomfort, leading to poor adherence to prescribed respiratory therapy.
- Delayed Recovery: Non-compliance with respiratory therapy results in inadequate oxygenation, increasing patient stress and delaying overall recovery.
The Solution
To address these challenges the hospital integrated Sleepnet’s Veraseal®3 Full Face Mask, engineered with soft-sealing AIR°gel® technology, into its portfolio of respiratory therapy therapies. Key features that addressed the hospital’s challenges included:
- Pressure Relief: The soft, pliable AIR°gel® adapts to the natural contours of the face, minimizing pressure points and supporting the prevention of facial ulcers by forming a seal without relying on excessive pressure.
- Improved Comfort: Designed to improve patient outcomes, the Veraseal®3 mask encourages longer wear times and better compliance.
- Skin Protection: The unique gel technology helps to reduce friction and irritation, which is especially beneficial for patients with fragile or sensitive skin.
Implementation
The hospital introduced Sleepnet’s Veraseal®3 Full Face mask as an option for patients requiring NIV therapy. The implementation process included:
- Training for Hospital Staff: Respiratory therapists and nursing staff received training on the benefits and proper fitting of Sleepnet’s Veraseal®3 Full Face mask masks to optimize patient outcomes.
- Pilot Program: A pilot study was conducted to evaluate the Veraseal® 3 Full Face Mask’s effectiveness in mitigating HAPIs among patients requiring NIV. The study focused on patient comfort, skin integrity, and seal performance within the hospital setting.
- Ongoing Monitoring: The hospital conducted periodic assessments to track patient compliance and monitor the incidence of pressure ulcers related to respiratory therapy masks.
Results
Within several months of integrating the Veraseal®3 mask into patient care, the hospital saw positive clinical and operational outcomes:
- Fewer Facial Pressure Injuries: Notable decline in the incidence of pressure ulcers among patients using the Veraseal®3.
- Greater Patient Satisfaction: Improved mask comfort led to better patient cooperation with NIV therapy.
- Faster Recovery and Reduced Costs: Higher compliance contributed to improved oxygenation, shorter stays, and reduced readmission risk.
Conclusion
The Veraseal®3 Full Face Mask, enhanced with Sleepnet’s AIR°gel® technology, proved to be a valuable tool in reducing the risk of pressure injuries and improving NIV therapy outcomes. Its integration not only increased patient comfort and compliance but also helped the hospital address broader concerns tied to cost and care efficiency.
Note: This use case does not disclose or publish identifying customer information.